Kite's Anito-cel Shows 96% Response Rate in Pivotal Multiple Myeloma Trial, Supporting 2026 Launch Plans
核心洞察
Kite (搜索) and Arcellx announced positive results from the pivotal iMMagine-1 Phase 2 study of anito-cel (搜索), showing a 96% overall response rate in heavily pretreated relapsed or refractory multiple myeloma (搜索) patients.
The CAR T-cell therapy demonstrated deep responses with 74% achieving stringent complete response and 95% achieving minimal residual disease negativity at median 15.9-month follow-up.
Safety profile was manageable with no delayed neurotoxicities observed, and the companies plan a 2026 U.S. launch for this BCMA (搜索)-directed therapy.
Kite (搜索), a Gilead Company, and partner Arcellx reported compelling efficacy data from their pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel (搜索)) at the 67th American Society of Hematology Annual Meeting. The investigational CAR T-cell therapy achieved a 96% overall response rate in patients with relapsed or refractory multiple myeloma (搜索) who had received at least three prior lines of therapy.
Exceptional Response Rates in Heavily Pretreated Population
The study enrolled 117 patients with a median follow-up of 15.9 months as of the October 7, 2025 data cutoff. An independent review committee assessed the overall response rate at 96%, with 74% of patients achieving stringent complete response or complete response per International Myeloma Working Group criteria. The patient population represented a challenging treatment scenario, with 87% being triple refractory, 41% penta refractory, 18% having extramedullary disease, and 40% presenting high-risk cytogenetics.
"These data are compelling and are an important advancement for patients living with multiple myeloma (搜索)," said Dr. Krina Patel, lead investigator and Associate Professor at The University of Texas MD Anderson Cancer Center. "I am encouraged by the depth of responses in the iMMagine-1 study. For clinicians, we rely on therapies that deliver continued meaningful efficacy, a predictable safety profile, and reliable manufacturing."
Responses occurred rapidly, with many patients responding within one month of treatment. The median time to best response was 4.8 months, while median time to stringent complete response or complete response was 3.2 months. Of 96 patients evaluable for minimal residual disease testing, 91 (95%) achieved negativity at a median time of one month, indicating undetectable cancer cells even with highly sensitive testing.
Sustained Survival Benefits
Progression-free survival rates demonstrated durability, with 82.1% of patients alive and progression-free at 12 months, 67.4% at 18 months, and 61.7% at 24 months. Overall survival rates showed 94% at 12 months, 88% at 18 months, and 83% at 24 months. Notably, median progression-free survival and overall survival have not yet been reached, suggesting sustained benefit for the majority of patients.
Manageable Safety Profile
The safety profile proved predictable and manageable across the study period. Cytokine release syndrome occurred in 86% of patients but was generally mild, with 83% experiencing no symptoms or only Grade 1 fever. Immune effector cell-associated neurotoxicity syndrome affected 8% of patients, with only one Grade 3 case and all others Grade 2 or lower.
Importantly, no delayed neurotoxicities were observed, including no cases of Parkinsonism, cranial nerve palsies, Guillain-Barré syndrome, or immune effector cell-associated enterocolitis among patients dosed at least 12 months prior to the data cutoff. The most common hematologic adverse events included neutropenia (71%), anemia (28%), and thrombocytopenia (26%). Grade 3 or higher infections occurred in 9% of patients.
Novel D-Domain Technology
Anito-cel (搜索) represents the first BCMA (搜索)-directed CAR T-cell therapy utilizing Arcellx's novel D-Domain binder technology. Preclinical research presented at ASH showed that the D-Domain binder interacts with BCMA through rapid binding and release, potentially reducing inflammation while maintaining cancer cell elimination capabilities. The therapy retains efficacy against cancer cells with altered BCMA expression following previous treatments, suggesting potential benefit in patients previously exposed to BCMA-targeting therapies.
Commercial Timeline and Market Impact
"For multiple myeloma (搜索) patients in advanced treatment stages, effective options are critical as resistance to treatment grows," said Cindy Perettie, Executive Vice President at Kite (搜索). "The deep, durable responses seen with iMMagine-1, combined with a predictable and manageable safety profile and rapid and reliable manufacturing, highlight anito-cel (搜索)'s potential to redefine care."
The companies plan to launch anito-cel (搜索) in the United States in 2026, with the goal of providing a differentiated, one-time treatment option that may reduce patient burden and improve access in outpatient and community oncology settings. Anito-cel has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA.
Study Design and Endpoints
The iMMagine-1 trial is a Phase 2 registrational, open-label study evaluating anito-cel (搜索) in patients with relapsed or refractory multiple myeloma (搜索) who received at least three prior regimens including proteasome inhibitor, immunomodulatory drugs, and anti-CD38 (搜索) antibody. Patients received a single infusion of anito-cel at a target dose of 115×10⁶ CAR+ viable T cells.
The primary endpoint is overall response rate per International Myeloma Working Group criteria as assessed by independent review committee. Secondary endpoints include complete response rate, progression-free survival, overall survival, duration of response, minimal residual disease negativity, and safety. Long-term safety data will be collected for up to 15 years in a separate follow-up study.